Ozempic has changed obesity management from lifestyle approaches to pharmacological treatments using GLP-1 receptor agonists to control appetite and glucose levels. These drugs, by enhancing satiety and slowing gastric emptying, support significant weight loss and diabetes management, addressing a global health crisis affecting over 650 million adults. The GLP-1 market has rapidly grown, with global sales projected to reach $100 billion by 2030. With numerous companies in the field, only one GLP-1 stock is identified as the best investment for 2025.
Ozempic's approval in 2017 transformed obesity treatment from lifestyle changes to drug-based interventions, utilizing GLP-1 to effectively regulate appetite and manage glucose.
The GLP-1 market is expanding rapidly, with global sales reaching $40 billion in 2024 and projected to soar to $100 billion by 2030, driven by the obesity epidemic.
Collection
[
|
...
]